

# Significance of Serum Procalcitonin Level in the Early Diagnosis of Neonatal Sepsis

Raid M. R. Umran<sup>1\*</sup>, Jasim M Hashim<sup>1</sup>, Husam Jameel<sup>2</sup>

1. Pediatrics Department, Faculty of Medicine, University of Kufa, Al-Zahraa Teaching Hospital, Najaf, Iraq

2. Pediatrics Department, Al-Zahraa Teaching Hospital, Najaf, Iraq

## ABSTRACT

**Background:** Sepsis in neonates presents itself with non-specific clinical features which makes early diagnosis difficult. However, procalcitonin (PCT) and other inflammatory markers have recently been considered as sensitive markers for the early detection of neonatal sepsis. Therefore, the present study aimed to determine the diagnostic value of PCT in the early detection of neonatal sepsis and compare it with C-reactive protein (CRP) and white blood cells count.

**Methods:** This case-control study was conducted on 40 neonates who were divided into two groups. The case or sepsis group consisted of 18 neonates with the clinical symptoms of sepsis and positive culture. On the other hand, the control group contained 22 healthy neonates with negative culture. Demographic characteristic of all the participants was recorded during the clinical follow-up. Moreover, blood samples were collected from each neonate for hematological analysis, blood culture, serum CRP measurement, and PCT analysis. Finally, all the collected data were statistically analyzed in SPSS software (version 17).

**Results:** Based on the findings, the mean value of the procalcitonin level was significantly higher in the sepsis group (866.60±480.51 pg/ml), compared with that of the control group (P<0.001). Moreover, the CRP was positive in 66.7% of sepsis patients and 22.7% of the control group (P=0.006). The procalcitonin level shows higher sensitivity (94%) than CRP (66%) with the same specificity but a higher positive and negative predictive value.

**Conclusion:** Procalcitonin level was elevated in neonates with sepsis in comparison to normal neonates and it is more sensitive than CRP. The PCT could be used as a routine test for the early diagnosis of neonatal sepsis which also leads to a reduction in the use of antibiotics.

**Keywords:** C-reactive protein, Diagnosis of sepsis, Neonatal sepsis, Procalcitonin

## Introduction

Despite the advances and developments in the field of neonatology, bacterial sepsis in neonates remains one of the most important reasons for neonatal mortality and morbidity around the world, especially in developing countries (1). Given the high mortality rate of neonatal bacterial sepsis and its nonspecific signs and symptoms, its early detection and treatment before positive culture are of great importance (2).

A definitive diagnosis of neonatal sepsis can only be made by blood culture which takes at least 24-48 h with a high false negative rate. This leads to the misuse of antibiotics and the treatment of many newborn infants who are clinically suspected to have bacterial sepsis (3).

This method is non-sensitive, non-specific, and usually associated with a substantial time delay (2, 3).

Inflammatory mediators, such as C-reactive protein (CRP), serum amyloid A, interleukins (IL-6, IL-8), and procalcitonin (PCT), were investigated as biomarkers of neonatal sepsis with various sensitivity and specificity. Despite the fact that these mediators were used in the diagnosis of bacterial neonatal sepsis, no single investigation has provided early and reliable detection of early bacterial infection and a combination of biomarkers was the best prediction used in the diagnosis (4).

A PCT is a peptide secreted in response to pro-

\* Corresponding author: Raid M. R. Umran, Pediatrics Department, Faculty of Medicine, University of Kufa, Al-Zahraa Teaching Hospital, Najaf, IRAQ. Tel: +9647801421961; Email: raed.mridha@uokufa.edu/iq

Please cite this paper as:

Umran RMR, Hashim JM, Jameel H. Significance of Serum Procalcitonin Level in the Early Diagnosis of Neonatal Sepsis. Iranian Journal of Neonatology. 2020 Sep; 11(3). DOI: [10.22038/ijn.2020.42296.1702](https://doi.org/10.22038/ijn.2020.42296.1702)

inflammatory stimuli, especially bacteria-induced inflammatory mediators (5). The actual biological role of PCT is still largely unknown; however, recent experimental studies show that it may have a pathogenic role in sepsis (6).

The PCT has the highest diagnostic accuracy and its level rises rapidly (within 6–12 h) after an infectious insult with systemic consequences. Beyond its value for the diagnosis of sepsis, PCT has also proved to be useful in monitoring the course and severity of the systemic inflammatory response (7).

Many studies have investigated the potential roles of PCT in the diagnosis and management of local and systemic infections. There is some evidence that PCT is highly specific for bacterial infections, with levels rising at the onset of infection and falling rapidly as the infection resolves by treatment, compared to other markers (8).

Recently, PCT has been increasingly used for the early detection of infection in adult and pediatric populations due to its sensitivity, specificity, rapid response, and short half-life (9).

It is mainly used in hospitals and seems to have a more diagnostic value than other known biomarkers of inflammation (10). It has attracted attention as a potential means for guidance on antibiotic stewardship, decrease of inappropriate antimicrobial use, and associated resistance (11).

The present case-control study aimed to determine the diagnostic value of PCT in the early detection of neonatal sepsis and compare it with CRP and WBC count.

## Methods

The present case-control study was conducted on the neonatal care unit of a secondary hospital in Iraq, from the first of April 2013 to the end of October 2013. In total, 60 neonates who were referred to the hospital due to suspicion of sepsis or hyperbilirubinemia were enrolled in the study. The demographic and clinical characteristics of the patients were recorded at the time of admission. Complete family and maternal histories were obtained and a thorough physical examination was performed by a trained senior house officer. Newborns with birth asphyxia, obvious or suspicious congenital anomalies, chromosomal anomalies, or any other dysmorphic features were excluded from the study.

Blood samples were obtained from each neonate prior to the commencement of the antibiotic treatment for the sepsis. Subsequently, the samples were sent for workup (complete

blood count (CBC), differential leucocyte count, blood cultures, cerebrospinal fluid (CSF) analysis and culture, and CRP and procalcitonin analysis), and radiological test if needed.

The CBC and white blood cell (WBC) differentiation were performed using the Sysmex automated hematology analyzer (KX-21N, manufactured by KOBE-JAPAN). The blood cultures were collected by adding one ml of blood to a blood culture media (screw caps) which contained bacterial activator (brain-heart infusion) and incubated at 37 °C for 3-5 days by Lab incubator (Termaks, Sweden ). Containers with positive growth were re-cultured on blood agar and Macconkey agar for 24 h. The isolated organisms were identified by standard bacteriological methods.

Serum CRP was measured by enzymatic heterogeneous sandwich immunoassay which is a latex agglutination test for qualitative and semi-quantitative determination of CRP in serum.

Serum Procalcitonin level was measured by immunoluminometric assay (ELIZA M6, USA). The PCT levels of > 250 pg/ml were considered positive. The CSF was collected from the patients and sent for cytology test, glucose level measurement, protein level measurement, and culture test.

According to the clinical signs and symptoms of sepsis and microbiological results of blood culture, 20 neonates with clinical suspicion of sepsis who had negative culture were excluded from the study. In total, 18 neonates with clinical signs and symptoms of sepsis and positive culture were enrolled in the study as the sepsis group. Moreover, 22 neonates who were healthy and visited the hospital for jaundice management or routine visit who had negative culture were allocated to the control group.

Informed consent was obtained from the parents of each patient. The study protocol was proved by the scientific and ethical committees of the hospital and the Faculty of Medicine at the University of Kufa, Najaf, Iraq.

## Statistical data analysis

Continuous variables were represented as the mean±SD and categorical variables were represented as frequency and percentages. The data were statistically analyzed in the SPSS software (version 17) using the t-test for the mean difference and chi-square ( $\chi^2$ ) and Mann-Whitney U tests for percentage differences and the odd ratio of categorical variables. Furthermore, sensitivity, specificity, positive predictive value

(PPV), and negative predictive value (NPV) were used for diagnostic efficiency. In addition, receiver operating characteristic (ROC) curves and the area under the curve were used to compare the sensitivity and specificity of the diagnostic procedures. A P-value of less than 0.05 was considered statistically significant.

## Results

The mean age of the sepsis group was  $10.88 \pm 11.5$  days while that of the control group was  $4.0 \pm 6.49$  days ( $P=0.022$ ). Moreover, 61% and 18% of the members in the sepsis and control groups were born through vaginal delivery, respectively ( $P=0.006$ ). Other characteristics show

no significant difference as shown in Table 1. Irritability, temperature instability, convulsion, bulging fontanelle, poor reflexes, pallor, distress, cyanosis, and the number of deaths were significantly more in the sepsis group, compared to the control group as shown in Table 1.

Procalcitonin level was significantly higher in the sepsis group ( $866.60 \pm 480.51$  pg/ml) compared with the control group ( $P < 0.001$ ). Furthermore, the CRP was positive in 66.7% and 22.7% of the sepsis and control groups, respectively ( $P=0.006$ ). While the white blood cell count and neutrophil percentage and lymphocyte percentage show no statistical difference as shown in (Table 2).

**Table 1.** Demographic characteristics and clinical features of the studied groups

| Parameters                    | Sepsis, N=18<br>N(percent) | Control, N=22<br>N(percent) | OR (95% CI)        | p-value |
|-------------------------------|----------------------------|-----------------------------|--------------------|---------|
| Age (day) (Mean $\pm$ SD)     | $10.88 \pm 11.5$           | $4.0 \pm 6.49$              | -                  | 0.022*  |
| Birth wt (kg) (Mean $\pm$ SD) | $2.60 \pm 0.61$            | $2.93 \pm 0.56$             | -                  | 0.88    |
| Gender: Male                  | 11(61)                     | 11(50)                      | 1.57(0.44 – 5.56)  | 0.488   |
| Preterm                       | 6(33)                      | 4(18)                       | 2.25(0.52 – 9.70)  | 0.277   |
| Delivery: NVD                 | 11(61)                     | 4(18)                       | 7.07(1.68 – 29.83) | 0.006   |
| CS                            | 7(39)                      | 18(82)                      |                    |         |
| lethargy                      | 13 (72.2)                  | 9 (40.9)                    | 3.77(0.99 – 14.29) | 0.051   |
| Irritability                  | 4 (22.2)                   | 0 (0)                       | 2.57(1.70 – 3.87)  | 0.021   |
| Poor feeding                  | 17 (94.4)                  | 19 (86.4)                   | 2.68(0.25 – 28.31) | 0.4     |
| Fever/cold                    | 17 (94.4)                  | 4 (18)                      | 10.0(1.77 – 55.98) | 0.004   |
| Convulsion                    | 6 (33.3)                   | 0 (0)                       | 2.83(1.80 – 4.47)  | 0.004   |
| Bulging fontanelle            | 7 (38.9)                   | 0 (0)                       | 3.0(1.85 – 4.86)   | 0.001   |
| Poor reflexes                 | 6 (33.3)                   | 2 (9.1)                     | 5.0(0.87 – 28.86)  | 0.06    |
| Pallor                        | 5 (27.8)                   | 0 (0)                       | 2.69(1.75 – 4.14)  | 0.009   |
| Jaundice                      | 3 (16.7)                   | 4 (18.2)                    | 0.90(0.17 – 4.67)  | 0.9     |
| Dyspnea                       | 8 (44.4)                   | 2 (9.1)                     | 8.0(1.43 – 44.92)  | 0.011   |
| Cyanosis                      | 4 (22.2)                   | 0 (0)                       | 2.57(1.70 – 3.87)  | 0.021   |
| Skin rash                     | 1 (5.6)                    | 0 (0)                       | 2.29(1.6 – 3.28)   | 0.27    |
| Death                         | 3(16.7)                    | 0(0)                        | 2.47(1.67 – 3.64)  | 0.049   |

CS: cesarean section, NVD: normal vaginal delivery, N: number, OR: odd ratio, SD: standard deviation, \*: independent sample t-test, other analysis used Mann-Whitney U test

**Table 2.** Hematology and blood tests of the study groups

| Parameters                | Sepsis (N=18)<br>Mean $\pm$ SD | Control (N=22)<br>Mean $\pm$ SD | p-value |
|---------------------------|--------------------------------|---------------------------------|---------|
| Procalcitonin pg/ml       | $866.60 \pm 480.51$            | $321.61 \pm 315.39$             | <0.001  |
| WBC count $\times 10^9/L$ | $15.08 \pm 5.95$               | $15.62 \pm 2.19$                | 0.722   |
| Neutrophils (percent)     | $55.67 \pm 15.06$              | $61.17 \pm 9.77$                | 0.192   |
| Lymphocytes (percent)     | $31.86 \pm 14.07$              | $31.17 \pm 8.31$                | 0.855   |
| CRP Positive, N(percent)  | 12 (66.7%)                     | 5 (22.7%)                       | 0.006*  |

CRP: C-reactive protein, N: number, SD: standard deviation, WBC: white blood cell, \*: Mann-Whitney U test, others used independent sample t-test.

The procalcitonin level shows higher sensitivity (94%) than CRP (66%) with the same specificity but more positive and negative predictive values as shown in Table 3.

The PCT level in the sepsis group shows a significantly higher area under the curve in the ROC curve than CRP, WBC count, and differential count ( $P=0.038$ ) as shown in Table 4 and Figure 1.

**Table 3.** Comparison of Validity tests of CRP and PCT with blood culture


| Validity test | CRP  | Procalcitonin |
|---------------|------|---------------|
| Sensitivity   | 66 % | 94 %          |
| Specificity   | 75 % | 77 %          |
| PPV           | 70 % | 75 %          |
| NPV           | 73 % | 85 %          |

CRP: C-reactive protein, NPV: negative predictive value, PPV: positive predictive value

**Table 4.** Receiver operating characteristic test and area under the curve for the sepsis group

| Test Result Variable(s) | Area Under the Curve |            |         | 95% Confidence Interval |             |
|-------------------------|----------------------|------------|---------|-------------------------|-------------|
|                         | Area                 | Std. Error | p value | Lower Bound             | Upper Bound |
|                         |                      |            |         |                         |             |
| PCT                     | 0.884                | 0.054      | 0.000   | 0.778                   | 0.990       |
| CRP                     | 0.280                | 0.084      | 0.018   | 0.116                   | 0.44        |
| WBC count               | 0.429                | 0.099      | 0.447   | 0.236                   | 0.623       |
| Neutrophils (percent)   | 0.578                | 0.092      | 0.399   | 0.399                   | 0.758       |
| Lymphocytes (percent)   | 0.562                | 0.096      | 0.511   | 0.375                   | 0.750       |

CRP: C-reactive protein, PCT: procalcitonin, WBC: white blood cells

**Figure 1.** Receiver operating characteristic curve and area under the curve for the laboratory parameters of the sepsis group

## Discussion

The CRP and PCT are only two examples of many mediators of infection which were investigated in severely ill neonates aiming to distinguish sepsis from noninfectious clinical presentation (12). Recently, the measurement of PCT and other biomarkers have been shown as a sensitive indicator for the rapid diagnosis and the outcome of neonatal sepsis (13, 14).

The present study investigated the serum level of PCT as an early diagnostic procedure for neonatal sepsis in comparison with CRP and WBC count and differential diagnosis in neonates with or without proven sepsis. The results revealed that the mean level of PCT in the culture-positive group was higher than that of the normal groups ( $P < 0.001$ ).

This finding was comparable with that of Minoo Adib et al. (15) and Zahedpasha et al. (16) who found that PCT levels were obviously increased in newborns with proven sepsis and the levels decreased rapidly after treatment by antibiotics. Moreover, many investigators had

found that PCT is a promising indicator for the early diagnosis of neonatal sepsis (13, 17, 18). These studies revealed that PCT is 83-100% sensitive and 70-100% specific in the early diagnosis of neonatal bacterial sepsis (17-19). In the present study, PCT sensitivity and specificity, PPV, and NPV with a cut-off level of more than 250 pg/ml were 94%, 77%, 75%, 85%, respectively. PCT was significantly more than CRP and WBC count and differential diagnosis ( $P = 0.038$ ) with more area under the ROC curve. These results were in line with those of a study performed by Chin YL et al. (20) who found that the sensitivity and specificity of PCT were 69.5% and 64.5%, respectively. Moreover, according to the above-mentioned study, the sensitivity and specificity of CRP were 67.25% and 93.9%, respectively. Adib M et al. (15) also found that the sensitivity and specificity of PCT were 75% and 80% respectively, while those of CRP were 45% and 95%, respectively.

Earlier studies had shown that there were

higher PCT levels in all neonates with proven or clinically suspected various types of neonatal sepsis (21-25). In a recent research Koksai et al. found that serum PCT level was superior to serum CRP level regarding the early diagnosis of neonatal sepsis, prediction of the severity of the illness, and the evaluation of the response to antibiotic treatment (26). On the other hand, Sakha K. et al. (27) proved that the serum levels of CRP and PCT are statistically different in the sepsis group with the CRP sensitivity and specificity being more than those of PCT.

Recent studies have concluded that PCT is not a perfect marker but it is the best available means for making individualized treatment decisions. The aim of such decisions is to decrease the duration of the antibiotic course of treatment or withhold these antibiotics for non-life-threatening respiratory tract infections (28, 29) and differentiating bacterial from nonbacterial meningitis (30).

Afshari and Harbarth (31) in their study concluded that there was a need for further clinical studies to investigate the procalcitonin and other biomarkers and indicators of sepsis, which will hopefully improve the antibiotic stewardship strategies in intensive-care units. The limitation of this study was its small scale and focus on one center. Moreover, the culture was falsely negative for clinically suspected sepsis and there was no other confirmatory procedure available to confirm sepsis.

## Conclusion

Procalcitonin level was elevated in neonatal sepsis, compared to normal neonates which is more sensitive and specific than CRP. PCT as an adjuvant with clinical signs and symptoms could be used as a routine test for the early diagnosis of neonatal sepsis and reduction of the use of antibiotics and hospital costs.

## Acknowledgments

The authors would like to deeply appreciate the cooperation of the laboratory department and lab technicians in Al-Zahra Teaching Hospital for their significant help in the analysis of the laboratory tests of the study.

## Conflicts of interest

The present study was not supported by any grant or fund. The authors declare that there was no conflict of interest in this study.

## References

1. Osrin D, Vergnano S, Costello A. Serious bacterial

- infections in newborn infants in developing countries. *Curr Opin Infect Dis.* 2004; 17(3):217-24.
2. Afroza S. Neonatal sepsis--a global problem: an overview. *Mymensingh Med J.* 2006; 15(1):108-14.
3. Naher BS, Mannan MA, Noor K, Shahidullah M. Role of serum procalcitonin and C-Reactive Protein in the diagnosis of neonatal sepsis. *Bangladesh Med Res Counc Bull.* 2011; 37(2):40-6.
4. Abdollahi A, Shoar S, Nayyeri F, Shariat M. Diagnostic value of simultaneous measurement of Procalcitonin, Interleukin-6 and hs-CRP in prediction of early-onset neonatal sepsis. *Mediterr J Hematol Infect Dis.* 2012; 4(1):e2012028.
5. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab.* 2004; 89(4):1512-25.
6. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. *Crit Care Med.* 2008; 36(3):941-52.
7. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. *Br J Pharmacol.* 2010; 159(2):253-64.
8. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. *Intensive Care Med.* 1998; 24(8):888-9.
9. Casado-Flores J, Blanco-Quiros A, Asensio J, Arranz E, Garrote JA, Nieto M. Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. *Pediatr Crit Care Med.* 2003; 4(2):190-5.
10. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. *Clin Microbiol Rev.* 2012; 25(4):609-34.
11. Harbarth S, Albrich WC, Muller B. When once is not enough--further evidence of procalcitonin-guided antibiotic stewardship. *Crit Care.* 2009; 13(4):165.
12. Enguix A, Rey C, Concha A, Medina A, Coto D, Diéguez MA. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. *Intensive Care Med.* 2001; 27(1):211-5.
13. Athhan F, Akagunduz B, Genel F, Bak M, Can D. Procalcitonin: a marker of neonatal sepsis. *J Trop Pediatr.* 2002; 48(1):10-4.
14. Gajewska E, Lachowska M. Usefulness of procalcitonin (PCT) as a marker of early-onset systemic infections in preterm newborns. *Med Sci Monit.* 2004; 10(2):33-5.
15. Adib M, Bakhshiani Z, Navaei F, Saheb Fosoul F, Fouladi S, Kazemzadeh H. Procalcitonin: a reliable marker for the diagnosis of neonatal sepsis. *Iran J Basic Med Sci.* 2012; 15(2):777-82.
16. Zahed PY, Ahmadpour KM, Haji AM, Haghshenas M. Procalcitonin as a marker of neonatal sepsis. *Iran J Pediatr.* 2009; 19(2):117-22.
17. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a

- marker of sepsis. *Int J Antimicrobe Agents*. 2002; 20(1):1-9.
18. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin-6 and interferon-alpha for differentiation of bacterial vs. viral infections. *Pediatr Infect Dis*. 1999; 18(10):875-81.
  19. Vincent JL. Procalcitonin: the marker of sepsis? *Crit Care Med*. 2000; 28(4):1226-8.
  20. Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department. *Critic Care*. 2004; 8(1):R12-20.
  21. Chiesa C, Panero A, Rossi N, Stegagno M, De Giusti M, Osborn JF. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. *Clin Infect Dis*. 1998; 26(3):664-72.
  22. Andrejaitiene J. The diagnostic value in severe sepsis. *Medicina (Kaunas)*. 2006; 42(1):69-78.
  23. Lapillonne A, Basson E, Monneret G, Bienvenu J, Salle BL. Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. *Lancet*. 1998; 351(9110):1211-2.
  24. Monneret G, Labaune JM, Isaac C, Bienvenu F, Putet G, Bienvenu J. Procalcitonin and C-reactive protein level in neonatal infections. *Acta Paediatr*. 1997; 86(2):209-12.
  25. Martin-Denavit T, Monneret G, Labaune JM, Isaac C, Bienvenu F, Putet G, et al. Usefulness of procalcitonin in neonates at risk for infection. *Clin Chem*. 1999; 45(3):440-1.
  26. Koksall N, Harmanci R, Getinkaya M, Hacimustafaoğlu M. Role of procalcitonin and CRP in diagnosis and follow up of neonatal sepsis. *Turk J Pediatr*. 2007; 49(1):21-9.
  27. Sakha K, Hussein MB, Seyyedsadri N. The role of the procalcitonin in the diagnosis of neonatal sepsis and correlation between procalcitonin and C-Reactive protein in the patients. *Pak J Biol Sci*. 2008; 11(14):1785-90.
  28. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*. 2012; 9:CD007498.
  29. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. *Intensive Care Med*. 2012; 38(6):940-9.
  30. Umran RM, Radhi NH. Diagnostic value of serum procalcitonin level in differentiating bacterial from nonbacterial meningitis in children. *Iran J Pediatr*. 2014; 24(6):739-44.
  31. Afshari A, Harbarth S. Procalcitonin as diagnostic biomarker of sepsis. *Lancet Infect Dis*. 2013; 13(5):382-4.